An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting

NCT06148935 | Recruiting

• 1 other identifier: 22013
• Study Type: observational
• Target: 1,350
• Locations: 1 country
• Sites: 1

Brief Summary

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in people with chronic heart failure with reduced ejection fraction (HFrEF). HFrEF is a long-term condition in which the heart does not pump blood as well as it should. Blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. Over time, heart failure can lead to other serious medical conditions that may result in hospital stays and death. The study treatment vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sGC). sGC helps to regulate the heart and blood circulation. Vericiguat has already been studied in previous clinical studies and is available for doctors to prescribe to people with heart failure. This study will collect important data from real-world setting in Korea. The participants of this study are people with HFrEF who will receive vericiguat as prescribed by their doctors according to the approved product information The main purpose of this study is to learn more about how safe vericiguat is in the participants. To do this, researchers will collect data on all medical problems (also called adverse events) that the participants have during the study. Doctors keep track of all adverse events, even if they do not think they might be related to the study treatment. Further, researchers will collect data on how well vericiguat works and treatment patterns in the participants. For this, the following information will be collected:

• occurrence of death due to heart and circulatory events
• hospital stays due to heart conditions (failure)
• dose levels of vericiguat and duration of treatment The data for this study will come from medical records and visits that take place in routine practice. Participants will be treated with vericiguat and observed up to 12 months or until death or they leave the study, whatever comes first.

Conditions

Chronic Heart Failure With Reduced Ejection Fraction

Outcome Measures

Primary Outcomes (1)

• Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs), serious adverse drug reactions (SADRs), unexpected adverse events (unexpected AEs) and unexpected adverse drug reactions (unexpected ADRs)

  From the date first administration of Verquvo (Vericiguat) to 14 days after the end of the treatment period, up to 12 months for each participant.

Secondary Outcomes (5)

• Occurrence of the composite of cardiovascular (CV) death or first hospitalization due to heart failure (HF)

  From initial visit to final visit, up to 12 months for each participant

• Occurrence of CV death

  From initial visit to final visit, up to 12 months for each participant

• Occurrence of HF hospitalization

  From initial visit to final visit, up to 12 months for each participant

• Time to reach different dose levels of Verquvo (Vericiguat) during initial titration

  From initial visit to final visit, up to 12 months for each participant

• Relative time on different dose levels of Verquvo (Vericiguat) during follow-up

  From first follow-up visit to final visit, up to 11 months for each participant

Study Arms (1)

Korean adult participants with HFrEF

Korean heart failure participants with reduced ejection fraction (HFrEF) who are prescribed Verquvo (Vericiguat) for an approved indication by the Ministry of Food and Drug Safety (MFDS) in Korea

Drug: Vericiguat (Verquvo, BAY1021189)

Interventions

Vericiguat (Verquvo, BAY1021189) DRUG

Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol

Korean adult participants with HFrEF

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Female and male participants with a diagnosis of heart failure with reduced ejection fraction (HFrEF) will be enrolled after the decision for treatment with Verquvo (Vericiguat) has been made by the investigator´s discretion.

You may qualify if:

• Adult aged 19 years or older
• Chronic HF (NYHA functional class II, III, or IV) Reduced left ventricular ejection fraction (\< 45%) within 12 months before enrollment
• Worsening of heart failure (hospitalized within 6 months before enrollment or intravenous diuretic therapy without hospitalization within 3 months)
• Participants who have been prescribed Verquvo (Vericiguat) as per locally approved label and didn't receive Verquvo (Vericiguat) therapy previously.
• Written informed consent from subject or legal representative; assent from subject when appropriate

You may not qualify if:

• Contraindication according to the local authorized label (including known hypersensitivity to the drug substance or any of its components, pregnancy)
• Participants participating in an investigational program with interventions outside of routine clinical practice

Sponsors & Collaborators

• Bayer: lead

Study Sites (1)

Many Locations

Multiple Locations, South Korea

RECRUITING

MeSH Terms

Interventions

vericiguat

Central Study Contacts

Bayer Clinical Trials Contact

CONTACT

(+)1-888-84 22937; clinical-trials-contact@bayer.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 20, 2023
• First Posted: November 28, 2023
• Study Start: November 30, 2023
• Primary Completion (Estimated): August 31, 2027
• Study Completion (Estimated): October 31, 2027
• Last Updated: April 17, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)